
Figure 1.

A.



* p=0.0008

B.




Figure 2.




Col4a3-/- + anti-miR-21
Col4a3-/-
WT
Percentage glomeruli
100
80
60
40
20
0
0
1
2
3
4
Sclerosis extent

Figure 3.

A.


Fibrosis
*
25
20
15
10
5
0
Sirius Red (%)
anti-miR-21
Control
* p=0.0002

B.





Col1a1
*
30
25
20
15
10
5
0
Fold Change
anti-miR-21
Control

Figure 4.

A.


Kidney injury rank score
12
10
8
6
4
2
0
*
anti-miR-21
Control

B.


% of Crescent
60
50
40
30
20
10
0
*
anti-miR-21
Control

C.




Tubule Injury (%)
*
anti-miR-21
Control

Figure 5.

A.


F4/80 + Area (%)
12
10
8
6
4
2
0
*
anti-miR-21
Control

B.




aSMA+ Area (%)
30
25
20
15
10
5
0
*
anti-miR-21
Control

Figure 6.

A.


Hydrogen peroxide
H2O2 (μM)
50
40
30
20
10
0
*
anti-miR-21
Control

B.



Avg DHE+ Area
40
30
20
10
0
*
Control
anti-miR-21
Col4a3-/-

Figure 7.





Figure 8.

A.


Weight (mg)
20
15
10
5
0 20 40 60 80 100 120
Days elapsed
**
Col4a3-/- PBS
Col4a3-/- anti-miR-21

B.





Percent survival
100
80
60
40
20
0
0 20 40 60 80 100 120
Days elapsed
***
Col4a3-/- PBS
Col4a3-/- anti-miR-21

Figure 9.

A.


BUN (mg/dL)
300
250
200
150
150
100
50
0
Wild type
Col4a3-/- PBS
Col4a3-/- 12.5 mg/kg
Col4a3-/- 25 mg/kg
Col4a3-/- 50 mg/kg
Col4a3-/- 25 mg/kg
QW
BIW

B.


Percent survival
100
75
50
25
0
Start of dosing
0
25
50
75
100
Age (days)
PBS
25 mg/kg twice weekly
50 mg/kg once weekly
25 mg/kg once weekly
12.5 mg/kg once weekly